• SyncroPatch 384/768i

    全球最高通量的全自动膜片钳系统
  • SyncroPatch 384/768i

    平行记录384个细胞 => 最高可升级到768个
  • SyncroPatch 384/768i

    真正的高通量与GΩ级封接
  • SyncroPatch 384/768i

    Analysis Software even more powerful than before
  • SyncroPatch 384/768i

    高科技保证实验的灵活性

2018 - Optogenetic technologies enable high throughput ion channel drug discovery and toxicity screening

icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) and   Icon CE   CardioExcyte 96 poster, Biophysics Annual Meeting 2018  logo pdf   (1.3 MB)

Contact:

This poster was presented by Axxam S.p.A and the University of Bonn in collaboration with Nanion (co-authors).

Abstract:

The drug discovery process involving ion channels needs to rely on high-throughput screening (HTS) assays as well as fine-tuned characterization by electrophysiological measurements. Combining optogenetic tools with induced pluripotent stem-cells (iPSC)-derived cardiomyocytes can provide a new reliable, cost-effective and highly time-resolved approach to induce electrogenic proteins activation. The aim of the OPTEL project, which combines the expertise of two leading European companies and one outstanding academic laboratory, was to develop integrated HTS-compatible platforms based on optogenetic tools (Channelrhodopsin, ChR2) for effective drug discovery in heterologous expression systems and iPS-derived cardiomyocytes. We generated HEK293 cell lines stably expressing ChR2 alone or with the cardiac sodium channel, NaV1.5 which proper functional expression was validated by fluorescence and manual patch-clamp. The best clones were used to implement light stimulation on an HTS automated patch-clamp platform (SynchroPatch 384PE, Nanion Technologies). We recorded light-induced currents and action potential-like responses in voltage and current-clamp, respectively, validating a new platform for high-throughput automated “opto-patch-clamp” assays. For optogenetic drug toxicity screening, commercially
available iPSC-derived cardiomyocytes were infected with adeno-associated viruses to express ChR2 and analyzed by recording extracellular field potentials from 96 wells with a modified CardioExcyte 96 system (Nanion Technologies). This was equipped with a custom designed 96 LED lid enabling pacing of cells and frequency-dependent drug screening over the physiological heart rate (1-3 Hz). Thereby we characterized adverse side effects of known ion channel blockers and pro-arrhythmogenic drugs on Na+, Ca2+ and K+ channel function. These results validate new platforms that allow optogenetic control of electrical activity in HTS-compatible format with four different readouts: fluorescence, electrophysiology, impedance and EFP. The use of these complementary readouts provides a new cost-effective and informative strategy in early stages of ion channel drug discovery, especially in the cardiac field.

返回总览  

SyncroPatch 384i brochure

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.